Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Not yet recruiting Phase 2 Interventional

Tirzepatide for the REduction of AceTazolamide in Idiopathic Intracranial Hypertension

ClinicalTrials.gov ID: NCT07946315

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07946315. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 6:43 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Tirzepatide for the REduction of AceTazolamide in Idiopathic Intracranial Hypertension: A Randomized, Double-Masked, Placebo-Controlled Phase 2 Trial of Adjunctive Tirzepatide

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The goal of this clinical trial is to learn if tirzepatide, a dual GIP/GLP-1 receptor agonist, helps to treat idiopathic intracranial hypertension (IIH) when added to acetazolamide, which is the standard medical therapy for IIH. The main questions it aims to answer are: * Does tirzepatide lower the mean daily acetazolamide dose at 12 months? * Does tirzepatide add-on therapy improve the likelihood of remission of IIH, improve weight loss, reduce cumulative acetazolamide exposure, improve ophthalmic outcome measures, improve normalization of intracranial hypertension as measured by lumbar puncture (LP) opening pressure, improve headache and quality of life measures and, improve MRI findings of intracranial hypertension? Investigators will compare tirzepatide to a placebo/sham injection in patients who are treated with a predefined dosing schedule of acetazolamide that adjusts based upon the response of papilledema and other IIH symptoms such as headache. In addition to receiving treatment with acetazolamide, participants will: * Receive weekly tirzepatide injections or a placebo/sham injection for 12 months, followed by 12 months of open-label observation. * Attend clinic visits at enrollment and months 1, 2, 3, 5, 7, 10, and 12 for neuro-ophthalmic examination and testing. * During other months meet with investigator or research assistant by phone for symptom documentation and medication adjustment. * Keep a record of any significant of days with headache for more than three hours or when a medication was taken for acute treatment of headache.

Study identification

NCT ID
NCT07946315
Recruitment status
Not yet recruiting
Study type
Interventional
Phase
Phase 2
Enrollment
75 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 55 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 1, 2027 (Estimated)
Primary completion
May 1, 2030 (Estimated)
Completion
May 1, 2030 (Estimated)
Last update posted
Nov 18, 2026

2027 – 2030

United States locations

U.S. sites
1
U.S. states
1
U.S. cities
1
Facility City State ZIP Site status
Brigham and Women's Hospital Boston Massachusetts 02446 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07946315, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 18, 2026 · Synced Nov 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.